Medical Dialogues

US Food and Drug Administration has approved  Inclisiran (Leqvio; Novartis) for lowering LDL cholesterol levels.

A significant association exists between statin adherence and ischemic and hemorrhagic stroke risk, hence it is necessary to stick to statin therapy.

India recorded 122 cases of the Omicron variant of COVID-19 in a span of 24 hours, the highest so far, Pushing its tally in the country to 358. The 358 Omicron Covid variant cases have been detected across 17 states and union territories so far.

The protection 3 offered by the Oxford-Astra Zeneca COVID-19 vaccine Declines after three months of receiving two doses of the preventive, according to a  study published in The Lancet journal.

Diabetes is a common chronic disease of childhood characterized by chronic hyperglycemia with end-organ damage that often results in the microvascular triad of nephropathy, neuropathy, and retinopathy.

Doctors Indemnity Not For Hospital: Supreme Court  

No Faculty In 5 Departments: NMC Inspection Points Out Faculty Shortage At Dumka Medical College  

Covishield Protection Diminishes After 3 Months: Lancet Study  

India's Omicron Cases Rise To 358 With 122 In Last 24 Hours   

Finally Molnupiravir Gets USFDA Nod  

FIR Against 3 SMS Hospital Doctors For Allegedly Molesting Colleague At Workplace

Statins reduces risk of ischemic, hemorrhagic stroke  

Diverse food within 1 year of life reduces allergy risk  

Oral tofacitinib helps in alopecia areata in children  

Antiseizure medication tied to lower vitamin D levels  

Type 2 DM children at high risk of developing retinopathy

Faster transmission of the Omicron virus and why third dose might be needed  

Irregular menses may indicate underlying CVD and diabetes  

FDA Approves tofacitinib for Treatment of Active Ankylosing Spondylitis  

Dental Anxiety highly prevalent amongst pregnant women  

Vitiligo patients have significantly increased odds of sensorineural hearing loss

Dental Anxiety is highly prevalent amongst pregnant women, according to a recent study published in the International Dental Journal.

The approval of XELJANZ for AS is based on data from a Phase 3, multicenter, randomized, double-blind, placebo-controlled study that evaluated the efficacy and safety of tofacitinib 5 mg twice daily versus placebo in 269 adult patients living with active AS.